Not yet recruiting NCT07317440
Coenzyme Q10 in Pediatric Community-Acquired Pneumonia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: oral coenzymeQ10.
- Who it may be relevant to
- Registry conditions: Community Acquired Pneumonia. Basic parameters: 2 months — 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia
Overview
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
Interventions
- Drug oral coenzymeQ10
60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
Primary outcome measures
- Normalization of respiratory rate [Time frame: 3 days]
- Normalization of temperature [Time frame: 3 days]
- Normalization of oxygen saturation [Time frame: 3 days]
- Normalization of Feeding Behavior Assessed by Oral Intake Tolerance [Time frame: 3 days]
- Serum C-Reactive Protein (CRP) Level [Time frame: 5 days]
- Serum Lactate Dehydrogenase (LDH) Level [Time frame: 5 days]
- Prognostic Nutritional Index [Time frame: 5 days]
- Systemic Immune-Inflammation Index [Time frame: 5 days]
- Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio) [Time frame: 5 days]
- Time of clinical stability [Time frame: 3-5 days]
Secondary outcome measures (2)
- Length of hospital stay [Time frame: 10-21 days]
- Number of Participants Requiring Surgical Intervention [Time frame: 21-30 days]
Eligibility criteria
Inclusion criteria
- All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia
Exclusion criteria
- Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT07317440 · 36264PR1169/3/25